Pfizer and BioNTech begin clinical trial for Omicron-specific vaccine
Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.
Stay updated with breaking news from Development Kathrin Jansen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.
"In the wake of omicron, we are proactively investigating and manufacturing at risk an omicron-based vaccine should it be needed," a spokesperson for Pfizer said.
"In the wake of omicron, we are proactively investigating and manufacturing at risk an omicron-based vaccine should it be needed," a spokesperson for Pfizer said.
"In the wake of omicron, we are proactively investigating and manufacturing at risk an omicron-based vaccine should it be needed," a spokesperson for Pfizer said.
"In the wake of omicron, we are proactively investigating and manufacturing at risk an omicron-based vaccine should it be needed," a spokesperson for Pfizer said.